Health and Me

Aarushi Bhadury

Being one of the most common cancer diagnoses, <span><a href="https://www.healthandme.com/health/skin-cancer">skin cancer</a></span> claims more than two people every hour. The Skin Cancer Foundation also specifies that having five or more sunburns doubles your risk of melanoma, which is a type of skin cancer. Despite the fact that people are often urged to wear sunscreen and take protection from heat, one in five Americans will develop skin cancer by the age of 70. However, the survival rate of melanoma is 99 percent, meaning if people can get it diagnosed early, they can get proper treatment. So, how can one get an early diagnosis? 

An experimental AI tool called PanDerm shows promising results in accelerating the detection of melanoma and other skin conditions, according to a new study published in Nature Medicine. When doctors used PanDerm, it improved the accuracy of <span>skin cancer diagnoses</span> by 11%, and the accurate diagnosis of other skin conditions by almost 17%. 

<h2>Enhancing Clinical Decision-Making </h2>

PanDerm is made in a way to assist doctors by helping them understand complex imaging data and make more confident and informed decisions. While a lot of people are skeptical of the use of AI and how it may impact human lives in the long rn, the study shows that using it to work alongside professionals can help us reach great medical heights. 

Researchers explained the tool is built to work alongside medical professionals, making it easier for them to interpret difficult images and choose the right course of action with greater certainty. This support is especially important because about 70% of people experience some kind of skin condition, making it crucial to spot them early for better treatment outcomes. 

Developed by a global research team, PanDerm was trained on a massive collection of over 2 million skin images, using four different types of medical imaging. Unlike previous AI models that struggled to combine various data types, PanDerm was specifically created to identify a wide range of skin conditions. It uses images from tiny microscopic slides to wide views showing lesions and the surrounding skin. 

Researchers also said that by training PanDerm with diverse data from different imaging techniques, they've created a system that can understand skin conditions similar to how dermatologists do—by combining information from various visual sources. 

<h2>Impressive Performance and Future Potential </h2>

In the study, PanDerm was tested on various tasks related to skin health, including screening for cancer, counting moles, tracking changes in lesions, and diagnosing a broad spectrum of skin conditions. The AI consistently delivered strong results, often needing only 5% to 10% of the data that doctors typically require for diagnoses. This means it can provide accurate results with much less information. 

This AI tool could be especially valuable in areas where it's hard to see a dermatologist, as researcher Peter Soyer pointed out. However, the researchers stress that PanDerm needs more evaluation and real-world testing in different healthcare settings and with various types of patients before it can be approved and widely used. 

The Cancer Research UK explains that when you have skin cancer, the main treatment is usually surgery. However, depending on where the cancer is, how big it is, and your overall health, you might have a different kind of treatment. Your doctor will discuss all the possible options with you. 

Besides surgery, other treatments include radiotherapy, which uses high-energy rays similar to X-rays to kill cancer cells, often for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). You might also get a chemotherapy cream that uses strong drugs to destroy cancer cells, or Imiquimod cream (Aldara), which helps your body's own defenses fight the cancer. 

For some types of skin cancer, doctors might suggest targeted drugs or immunotherapy. These treatments either attack specific parts of cancer cells or boost your immune system to help it kill the cancer. Another option is photodynamic therapy (PDT), which uses a special drug and light to destroy the cancer cells. 

After you finish your skin cancer treatment, you'll need to have follow-up appointments to make sure everything is okay. 

Health Conditions A-Z

health

Skin Cancer

Skin Cancer Diagnoses with the help of AI

AI helps skin cancer diagnosis

Cancer Diagnosis and AI

Cancer Diagnosis with the help of AI

Skin Cancer Diagnoses

Do Covid-19 At-Home Tests Detect The New Variants?

Wildfire Smoke Could Fuel Flu And COVID-19 Outbreaks

Skin Cancer Diagnoses See A Boost With The Help Of AI

Health & Wellness

High-Carb Foods That Are Really Healthy

Dementia Vs Alzheimer’s: Difference Explained Under 60 Seconds

Healthy Staple Foods To Make Eating Healthy Easier

Are You Dealing With Abandonment Issues? Signs And Risk Factors

Mid-Work Healthy Snacks You Can Eat Throughout The Day

Common Mistakes You May Be Making In The Gym

Strengthen Your Legs Muscles With These Exercises

Beat Anxiety With Books: How Reading Helps With Stress

Ghee For Health: Ayurvedic Health Benefits Of Clarified Butter

Common Mistakes You Are Making While Walking

Exercises You Should Do At Home When You Skip Gym

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

Healthy Drinks That Improve Your Digestion

World Tobacco Day: Unexpected Ways Smoking Can Affect You

Seasonal Mood Swings? How Weather Affects Mental Health

Is Calorie Counting Healthy? Dos And Don’ts

Heat-Related Illnesses That You Should Know

Menstrual Hygiene Day: Tips On Period Hygiene

​Add These High Protein Vegetarian Meals To Your Diet​

Top 10 Workouts That Burn Most Calorie

Makhana Season – Healthy &amp; Quick Foxnut Recipes

Being one of the most common cancer diagnoses, skin cancer claims more than two people every hour. The Skin Cancer Foundation also specifies that having five or more sunburns doubles your risk of melanoma, which is a type of skin cancer. Despite the fact that people are often urged to wear sunscreen and take protection from heat, one in five Americans will develop skin cancer by the age of 70. However, the survival rate of melanoma is 99 percent, meaning if people can get it diagnosed early, they can get proper treatment. So, how can one get an early diagnosis? An experimental AI tool called PanDerm shows promising results in accelerating the detection of melanoma and other skin conditions, according to a new study published in Nature Medicine. When doctors used PanDerm, it improved the accuracy of skin cancer diagnoses by 11%, and the accurate diagnosis of other skin conditions by almost 17%. Enhancing Clinical Decision-Making PanDerm is made in a way to assist doctors by helping them understand complex imaging data and make more confident and informed decisions. While a lot of people are skeptical of the use of AI and how it may impact human lives in the long rn, the study shows that using it to work alongside professionals can help us reach great medical heights. Researchers explained the tool is built to work alongside medical professionals, making it easier for them to interpret difficult images and choose the right course of action with greater certainty. This support is especially important because about 70% of people experience some kind of skin condition, making it crucial to spot them early for better treatment outcomes. How PanDerm Works Developed by a global research team, PanDerm was trained on a massive collection of over 2 million skin images, using four different types of medical imaging. Unlike previous AI models that struggled to combine various data types, PanDerm was specifically created to identify a wide range of skin conditions. It uses images from tiny microscopic slides to wide views showing lesions and the surrounding skin. Researchers also said that by training PanDerm with diverse data from different imaging techniques, they've created a system that can understand skin conditions similar to how dermatologists do—by combining information from various visual sources. Impressive Performance and Future Potential In the study, PanDerm was tested on various tasks related to skin health, including screening for cancer, counting moles, tracking changes in lesions, and diagnosing a broad spectrum of skin conditions. The AI consistently delivered strong results, often needing only 5% to 10% of the data that doctors typically require for diagnoses. This means it can provide accurate results with much less information. This AI tool could be especially valuable in areas where it's hard to see a dermatologist, as researcher Peter Soyer pointed out. However, the researchers stress that PanDerm needs more evaluation and real-world testing in different healthcare settings and with various types of patients before it can be approved and widely used. Treatment For Skin Cancer The Cancer Research UK explains that when you have skin cancer, the main treatment is usually surgery. However, depending on where the cancer is, how big it is, and your overall health, you might have a different kind of treatment. Your doctor will discuss all the possible options with you. Besides surgery, other treatments include radiotherapy, which uses high-energy rays similar to X-rays to kill cancer cells, often for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). You might also get a chemotherapy cream that uses strong drugs to destroy cancer cells, or Imiquimod cream (Aldara), which helps your body's own defenses fight the cancer. For some types of skin cancer, doctors might suggest targeted drugs or immunotherapy. These treatments either attack specific parts of cancer cells or boost your immune system to help it kill the cancer. Another option is photodynamic therapy (PDT), which uses a special drug and light to destroy the cancer cells. After you finish your skin cancer treatment, you'll need to have follow-up appointments to make sure everything is okay. 

skin cancer diagnoses see a boost with the help of ai

Health News

XFG COVID Variant Now Dominant In Maharashtra Amid Rising Infections, Flags Genome Study

xfg covid variant now dominant in maharashtra amid rising infections, flags genome study

India’s COVID-19 Tally Falls To 6,483, Here Are Step-by-Step Home Isolation Guidelines

india’s covid-19 tally falls to 6,483, here are step-by-step home isolation guidelines

Can Wildfires Increase The Risk Of COVID-19 And Flu?

can wildfires increase the risk of covid-19 and flu?

New HIV Prevention Shot Approved — But Access Remains A Question

new hiv prevention shot approved — but access remains a question

In many ways <span>COVID</span>-19 has changed the way medicine and treatments work. During peak COVID wave, at-home test kits became a more accepted part of medical care for people, as stepping outside and visiting hospitals could also cause infection. As new strains of COVID keep mutating, many people have brought up concerns regarding the effectiveness of the at-home tests. 

The concern is regarding the fact that these at-home test kits are equipped to diagnose the new strains or are there certain strains that can go undetected. 

If you start feeling sick with symptoms like a cough, fever, or runny nose, you might worry if it's <span>COVID-19</span>. A simple way to check is by using an at-home COVID-19 test. You can easily find these tests at drugstores, supermarkets, and online stores. 

At-home COVID-19 tests are designed to find tiny parts of the SARS-CoV-2 virus, which causes COVID-19. These parts are called antigens. Rapid at-home antigen tests usually give you results in about 15 minutes. If your test is positive, it's very likely you have the virus. 

It's important to know that these tests can sometimes give a false negative, meaning you could test negative but still have the virus. However, because these tests are quick and rarely give a false positive, they can be very useful if used correctly.

<h2>Do They Work Against New COVID Variants? </h2>

At-home COVID tests should work against newer versions of the virus, “The antigen, that the at-home tests look for has remained fairly stable even as the virus mutates and new strains of COVID develop”. Harvard Health experts explain that the part of the virus these tests look for stays pretty much the same, even as the virus changes. Research generally shows that these antigen tests are good at finding different COVID-19 variants. 

In a comparative study published in the Microbiology Spectrum journals, researchers looked at 2 types of tests PCR test and rapid antigen tests (Ag-RDTs). They used FIA which is the flourescence immunoassay, a simple and rapid technique that is used to measure compounds like drugs, hormones and proteins and LFIA which is lateral flow immunoassay, that is also used to detect proteins, haptens (a type of molecules), nucleic acids etc. Both rapid tests were 100% accurate at finding the virus when there was a lot of virus in the sample. However, their ability to find the virus dropped to around 30% when there was only a small amount of virus present. 

This study confirms that rapid antigen tests (especially FIA and LFIA) work almost as well as RT-PCR tests for finding SARS-CoV-2. The FIA test was particularly good for people who had the virus but no symptoms. Both rapid tests agreed strongly with the gold standard RT-PCR results. 

Harvard Health experts advise using an at-home COVID test if you have respiratory symptoms like a cough, fever, or runny nose. She also suggests testing if you've been around someone with COVID-19, or if you're going to be near elderly people or those with weak immune systems who could get very sick from the virus. 

In general, these tests are most effective when you have symptoms. One study found that certain at-home tests caught almost 90% of COVID cases in people with symptoms, but only about half of cases in people who had the virus but no symptoms. 

If your test is positive, it means you have the virus. If it is negative, health authorities recommend taking another test 48 hours later to reduce the chance of a false negative. 

If you have respiratory symptoms, these combination tests are an easy way to find out if you have the flu, COVID-19, or both, without needing to visit a doctor's office. You can also help public health efforts by reporting your test result (whether it's positive or negative) online. 

The best way to protect yourself from both COVID-19 and the flu is to get vaccinated for both. Vaccines lower your risk of getting sick and developing serious complications if you do catch the viruses. 

covid

Covid-19

Covid-19 at home test kits

Are Covid-19 At-Home Tests Useful

do At-Home COVID Tests Work?

How accurate are At-Home COVID Tests

Can At-Home COVID Tests Detect new strains

At-Home COVID Tests Kits

In many ways COVID-19 has changed the way medicine and treatments work. During peak COVID wave, at-home test kits became a more accepted part of medical care for people, as stepping outside and visiting hospitals could also cause infection. As new strains of COVID keep mutating, many people have brought up concerns regarding the effectiveness of the at-home tests. The concern is regarding the fact that these at-home test kits are equipped to diagnose the new strains or are there certain strains that can go undetected. How At-Home COVID Tests Work? If you start feeling sick with symptoms like a cough, fever, or runny nose, you might worry if it's COVID-19. A simple way to check is by using an at-home COVID-19 test. You can easily find these tests at drugstores, supermarkets, and online stores. At-home COVID-19 tests are designed to find tiny parts of the SARS-CoV-2 virus, which causes COVID-19. These parts are called antigens. Rapid at-home antigen tests usually give you results in about 15 minutes. If your test is positive, it's very likely you have the virus. It's important to know that these tests can sometimes give a false negative, meaning you could test negative but still have the virus. However, because these tests are quick and rarely give a false positive, they can be very useful if used correctly. Do They Work Against New COVID Variants? At-home COVID tests should work against newer versions of the virus, “The antigen, that the at-home tests look for has remained fairly stable even as the virus mutates and new strains of COVID develop”. Harvard Health experts explain that the part of the virus these tests look for stays pretty much the same, even as the virus changes. Research generally shows that these antigen tests are good at finding different COVID-19 variants. In a comparative study published in the Microbiology Spectrum journals, researchers looked at 2 types of tests PCR test and rapid antigen tests (Ag-RDTs). They used FIA which is the flourescence immunoassay, a simple and rapid technique that is used to measure compounds like drugs, hormones and proteins and LFIA which is lateral flow immunoassay, that is also used to detect proteins, haptens (a type of molecules), nucleic acids etc. Both rapid tests were 100% accurate at finding the virus when there was a lot of virus in the sample. However, their ability to find the virus dropped to around 30% when there was only a small amount of virus present. This study confirms that rapid antigen tests (especially FIA and LFIA) work almost as well as RT-PCR tests for finding SARS-CoV-2. The FIA test was particularly good for people who had the virus but no symptoms. Both rapid tests agreed strongly with the gold standard RT-PCR results. When to Test for COVID? Harvard Health experts advise using an at-home COVID test if you have respiratory symptoms like a cough, fever, or runny nose. She also suggests testing if you've been around someone with COVID-19, or if you're going to be near elderly people or those with weak immune systems who could get very sick from the virus. In general, these tests are most effective when you have symptoms. One study found that certain at-home tests caught almost 90% of COVID cases in people with symptoms, but only about half of cases in people who had the virus but no symptoms. If your test is positive, it means you have the virus. If it is negative, health authorities recommend taking another test 48 hours later to reduce the chance of a false negative. If you have respiratory symptoms, these combination tests are an easy way to find out if you have the flu, COVID-19, or both, without needing to visit a doctor's office. You can also help public health efforts by reporting your test result (whether it's positive or negative) online. The best way to protect yourself from both COVID-19 and the flu is to get vaccinated for both. Vaccines lower your risk of getting sick and developing serious complications if you do catch the viruses. 

do covid-19 at-home tests detect the new variants?

Dementia Caregivers Have A Higher Chance Of Getting Dementia Themselves

dementia caregivers have a higher chance of getting dementia themselves

Asthma Risk Could Increase For Women Who Work Night Shifts: Study

asthma risk could increase for women who work night shifts: study

Wildfires are a big concern for US citizens. Since the beginning of 2025, 31,039 wildfires have consumed 1.3 million acres of US land, according to the National Interagency Fire Center. Wildfires are uncontrolled fires that burn wildland and often rural areas. These fires can exhaust forests, grasslands, and many other ecosystems. With the amount of smoke generated, wildfires can severely affect the health of people. 

A new study suggests that wildfires might indirectly raise the risk of flu and <span>COVID-19 outbreaks</span>. The smoke from wildfires often forces people to stay indoors, and when more people are gathered in enclosed spaces, infectious diseases can spread more easily. This finding was recently published in the journal PLOS Climate. 

<h2>Why Staying Inside Puts You at Higher Risk </h2>

When wildfires burn, the air outside gets filled with smoke, making people go indoors. This creates perfect conditions for illnesses like the flu to spread, as a researcher from Georgetown University explained. With more people packed together, germs can jump from one person to another more easily. But there's a simple way to lower this risk: just wearing a mask indoors can help a lot. 

<h2>Following People's Movements During Wildfires </h2>

Researchers looked at mobile phone data to see where people went during wildfires. This data showed visits to over 4.6 million places across the U.S., both inside and outside. They focused on the wildfire season in Oregon and Washington in 2020. By checking air quality, they found the areas worst affected by smoke. During that time, especially in August and September 2020, widespread wildfires caused a lot of smoke in these states. 

The study found a clear increase in indoor activities when the wildfires were burning. In counties across Oregon, indoor activity went up by 14%, and in Washington counties, it increased by almost 11%. Major cities also saw a significant jump: Seattle experienced a 16% rise, and Portland saw an 11% increase in people spending time indoors. This shift means more people were confined together. 

Using computer models, the researchers confirmed that more people indoors raises the risk of infectious diseases spreading, especially for highly contagious illnesses like flu and COVID-19. But these models also showed that wearing masks indoors can help slow the spread. They found that even a small increase in mask wearing (just 10% more people) could lower the number of new cases during wildfires. In areas hit hardest by smoke, like parts of Oregon and Washington, more than half the people might need to wear masks to effectively control the disease.

<h2>Preparing for Health Risks in a Changing Climate </h2>

The researchers advise public health experts to be aware of this connection if <span>wildfire smoke</span> reaches their communities. They should also warn people about the higher risk of infection. The study emphasized that as we face more extreme weather events, our public health plans need to change. We have to address not just the direct environmental harm from wildfires, but also how people react and adapt to these emergencies. By understanding how people behave and planning for it, we can better protect everyone's health in a world where extreme events are becoming more common. 

Wildfire Smoke

covid 19

Wildfire Smoke and Flu

Wildfire Smoke and health issues

COVID-19 Outbreaks

Wildfire smoke and covid 19

Wildfires are a big concern for US citizens. Since the beginning of 2025, 31,039 wildfires have consumed 1.3 million acres of US land, according to the National Interagency Fire Center. Wildfires are uncontrolled fires that burn wildland and often rural areas. These fires can exhaust forests, grasslands, and many other ecosystems. With the amount of smoke generated, wildfires can severely affect the health of people. A new study suggests that wildfires might indirectly raise the risk of flu and COVID-19 outbreaks. The smoke from wildfires often forces people to stay indoors, and when more people are gathered in enclosed spaces, infectious diseases can spread more easily. This finding was recently published in the journal PLOS Climate. Why Staying Inside Puts You at Higher Risk When wildfires burn, the air outside gets filled with smoke, making people go indoors. This creates perfect conditions for illnesses like the flu to spread, as a researcher from Georgetown University explained. With more people packed together, germs can jump from one person to another more easily. But there's a simple way to lower this risk: just wearing a mask indoors can help a lot. Following People's Movements During Wildfires Researchers looked at mobile phone data to see where people went during wildfires. This data showed visits to over 4.6 million places across the U.S., both inside and outside. They focused on the wildfire season in Oregon and Washington in 2020. By checking air quality, they found the areas worst affected by smoke. During that time, especially in August and September 2020, widespread wildfires caused a lot of smoke in these states. More People, More Risk The study found a clear increase in indoor activities when the wildfires were burning. In counties across Oregon, indoor activity went up by 14%, and in Washington counties, it increased by almost 11%. Major cities also saw a significant jump: Seattle experienced a 16% rise, and Portland saw an 11% increase in people spending time indoors. This shift means more people were confined together. Using computer models, the researchers confirmed that more people indoors raises the risk of infectious diseases spreading, especially for highly contagious illnesses like flu and COVID-19. But these models also showed that wearing masks indoors can help slow the spread. They found that even a small increase in mask wearing (just 10% more people) could lower the number of new cases during wildfires. In areas hit hardest by smoke, like parts of Oregon and Washington, more than half the people might need to wear masks to effectively control the disease. Preparing for Health Risks in a Changing Climate The researchers advise public health experts to be aware of this connection if wildfire smoke reaches their communities. They should also warn people about the higher risk of infection. The study emphasized that as we face more extreme weather events, our public health plans need to change. We have to address not just the direct environmental harm from wildfires, but also how people react and adapt to these emergencies. By understanding how people behave and planning for it, we can better protect everyone's health in a world where extreme events are becoming more common. 

wildfire smoke could fuel flu and covid-19 outbreaks

Tanya Dutt

FDA Approves HIV Shot That’s 99.9% Effective; Is This The Beginning Of The End For The Viral Epidemic?

988 Hotline Halt: Trump Administration Will Stop National Suicide & Crisis Lifeline  For LGBTQ+ Youth From July On

988 hotline halt: trump administration will stop national suicide & lifeline crisis for lgbtq+ youth from july on

No HPV Or Meningitis Shots On Agenda As RFK Jr.’s CDC Panel Focuses On Controversial Vaccine Debate

no hpv or meningitis shots on agenda as rfk jr.’s cdc panel focuses on controversial vaccine debate

As US Measles Cases Climb To Nearly 1,200, Over 3% Of The Infected Population Were Fully Vaccinated

as us measles cases climb to nearly 1,200, over 3% of the infected population were fully vaccinated

The U.S. Food and Drug Administration (FDA) approved Yeztugo, a powerful, long-acting injection developed by Gilead Sciences, as a twice-yearly preventive treatment against HIV. The move has ignited widespread hope among global health advocates, signaling what many believe to be the dawn of a new era in HIV prevention.

With a 99.9% success rate in preventing HIV transmission in clinical trials, this injectable therapy formally known as lenacapavir, offers a revolutionary alternative to daily pills and could dramatically reshape the global HIV landscape.

<h2>Why Is <span rel="noindex">HIV Drug</span> Approval Such a Big Deal?</h2>

For more than 40 years, HIV has eluded a vaccine. While treatment has transformed HIV into a manageable chronic condition for millions, preventing new infections has remained a formidable challenge. Daily oral PrEP (pre-exposure prophylaxis), such as Truvada, has helped, but adherence is difficult for many especially in vulnerable populations.

That’s where Yeztugo changes the game. Its unique mechanism, longevity, and ease of use have the potential to overcome the barriers of daily pill regimens. Administered once every six months by a healthcare provider, it’s the longest-lasting PrEP option ever approved.

“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, CEO of Gilead Sciences. “We believe this marks a turning point.”

Lenacapavir is not a vaccine. Instead, it is an antiretroviral that blocks HIV from infecting immune cells and replicating. What sets it apart is its ability to stay in the body for extended periods, providing protection for six months with a single shot.

Gilead conducted two major trials to test the drug’s efficacy in over 2,000 cisgender women in sub-Saharan Africa, the injection showed 100% prevention of HIV infection.

A parallel trial involving men who have sex with men and gender-diverse individuals showed a 99.9% effectiveness rate, with only two breakthrough infections. These outcomes, published in The New England Journal of Medicine, led Science to name lenacapavir its 2024 “Breakthrough of the Year.”

Reported side effects were minimal, limited mostly to injection site irritation, headaches, and nausea.

<h2>How The New Drug Affects HIV Treatment And Prevention?</h2>

Interestingly, lenacapavir didn’t start as a preventive drug. It was initially approved in 2022 (under the brand name Sunlenca) for treating drug-resistant HIV.

Researchers at Gilead quickly recognized two features that made it ideal for prevention: its long half-life and its ability to disrupt multiple stages of the HIV life cycle.

“We saw a fantastic protective effect after just one injection—even in non-human primate studies,” said Tomas Cihlar, Gilead’s VP of Virology. “That’s when we realized we had to pursue prevention aggressively.”

In many ways, yes—at least for now. While lenacapavir isn’t a vaccine in the traditional sense, its efficacy closely mimics one. And since traditional HIV vaccine development has repeatedly hit roadblocks, some experts believe lenacapavir may be the next best thing.

“Lenacapavir used by itself for prevention is a huge breakthrough,” said Dr. David Ho of Columbia University, a pioneer in HIV research. “Its potential to curb the epidemic is enormous.”

Yet ironically, the drug’s success could make it harder to develop a conventional vaccine. Why? Because it would now be unethical to assign people a placebo in vaccine trials when such a highly effective alternative exists.

While the science is exciting, several real-world challenges could stand in the way of Yeztugo’s success, cost, access, and policy chief among them.

Previous injectable PrEP options like cabotegravir, approved in 2021, came with hefty price tags and have yet to make a meaningful global impact. Gilead has not yet announced pricing for Yeztugo, but there’s concern it may follow suit.

Additionally, logistical barriers remain. Yeztugo must be administered in a clinic by a healthcare provider and requires that recipients test negative for HIV before each shot. That’s a significant hurdle for high-risk individuals in low-resource settings.

“There’s huge promise here, but we’ve built a jet without a runway,” said Hui Yang of the Global Fund to Fight HIV, TB, and Malaria. “If we don’t address distribution, affordability, and systemic barriers, the science won’t matter.”

<h2>Who Gets Access To HIV Injection?</h2>

Gilead has signed royalty-free licensing deals with six manufacturers to produce lenacapavir generics in 120 low- and middle-income countries. But critics point out that many middle-income nations, such as some in Latin America, are left out.

Meanwhile, in the U.S., states with strong support for PrEP programs have already seen a 38% decline in HIV infections. In contrast, states without similar support saw a 27% increase, according to The Lancet HIV.

With Medicaid cuts looming and the Supreme Court considering a case that could overturn the requirement for insurers to cover PrEP without copays, the long-term reach of Yeztugo may be compromised.

“We could be standing on the verge of eliminating new HIV infections,” said Carl Schmid of the HIV+Hepatitis Policy Institute. “But without the right policies, this will remain a medical miracle out of reach for too many.”

<h2>What Comes Next In the HIV Battle?</h2>

Gilead is already working on a once-a-year formulation of lenacapavir to make prevention even more accessible. The Global Fund aims to reach two million new PrEP users in the next three years, and Yeztugo could be pivotal to that goal.

There’s also ongoing research into self-administered versions of the injection, which would help reduce the need for in-clinic visits—especially vital for reaching marginalized populations.

The FDA’s approval of Yeztugo is more than a regulatory milestone—it’s a paradigm shift in HIV prevention strategy. Whether this breakthrough can live up to its promise will depend on how quickly and equitably it can be delivered.

hiv drug

yeztugo hiv injection

fda hiv drug approval

lenacapavir prep shot

hiv prevention 2025

gilead hiv breakthrough

twice yearly hiv treatment

hiv prep injection approval

The U.S. Food and Drug Administration (FDA) approved Yeztugo, a powerful, long-acting injection developed by Gilead Sciences, as a twice-yearly preventive treatment against HIV. The move has ignited widespread hope among global health advocates, signaling what many believe to be the dawn of a new era in HIV prevention.With a 99.9% success rate in preventing HIV transmission in clinical trials, this injectable therapy formally known as lenacapavir, offers a revolutionary alternative to daily pills and could dramatically reshape the global HIV landscape.Why Is HIV Drug Approval Such a Big Deal?For more than 40 years, HIV has eluded a vaccine. While treatment has transformed HIV into a manageable chronic condition for millions, preventing new infections has remained a formidable challenge. Daily oral PrEP (pre-exposure prophylaxis), such as Truvada, has helped, but adherence is difficult for many especially in vulnerable populations.That’s where Yeztugo changes the game. Its unique mechanism, longevity, and ease of use have the potential to overcome the barriers of daily pill regimens. Administered once every six months by a healthcare provider, it’s the longest-lasting PrEP option ever approved.“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, CEO of Gilead Sciences. “We believe this marks a turning point.”How Does Yeztugo Work?Lenacapavir is not a vaccine. Instead, it is an antiretroviral that blocks HIV from infecting immune cells and replicating. What sets it apart is its ability to stay in the body for extended periods, providing protection for six months with a single shot.Gilead conducted two major trials to test the drug’s efficacy in over 2,000 cisgender women in sub-Saharan Africa, the injection showed 100% prevention of HIV infection.A parallel trial involving men who have sex with men and gender-diverse individuals showed a 99.9% effectiveness rate, with only two breakthrough infections. These outcomes, published in The New England Journal of Medicine, led Science to name lenacapavir its 2024 “Breakthrough of the Year.”Reported side effects were minimal, limited mostly to injection site irritation, headaches, and nausea.How The New Drug Affects HIV Treatment And Prevention?Interestingly, lenacapavir didn’t start as a preventive drug. It was initially approved in 2022 (under the brand name Sunlenca) for treating drug-resistant HIV.Researchers at Gilead quickly recognized two features that made it ideal for prevention: its long half-life and its ability to disrupt multiple stages of the HIV life cycle.“We saw a fantastic protective effect after just one injection—even in non-human primate studies,” said Tomas Cihlar, Gilead’s VP of Virology. “That’s when we realized we had to pursue prevention aggressively.”Could This Replace HIV Vaccine?In many ways, yes—at least for now. While lenacapavir isn’t a vaccine in the traditional sense, its efficacy closely mimics one. And since traditional HIV vaccine development has repeatedly hit roadblocks, some experts believe lenacapavir may be the next best thing.“Lenacapavir used by itself for prevention is a huge breakthrough,” said Dr. David Ho of Columbia University, a pioneer in HIV research. “Its potential to curb the epidemic is enormous.”Yet ironically, the drug’s success could make it harder to develop a conventional vaccine. Why? Because it would now be unethical to assign people a placebo in vaccine trials when such a highly effective alternative exists.Is There A the Catch?While the science is exciting, several real-world challenges could stand in the way of Yeztugo’s success, cost, access, and policy chief among them.Previous injectable PrEP options like cabotegravir, approved in 2021, came with hefty price tags and have yet to make a meaningful global impact. Gilead has not yet announced pricing for Yeztugo, but there’s concern it may follow suit.Additionally, logistical barriers remain. Yeztugo must be administered in a clinic by a healthcare provider and requires that recipients test negative for HIV before each shot. That’s a significant hurdle for high-risk individuals in low-resource settings.“There’s huge promise here, but we’ve built a jet without a runway,” said Hui Yang of the Global Fund to Fight HIV, TB, and Malaria. “If we don’t address distribution, affordability, and systemic barriers, the science won’t matter.”Who Gets Access To HIV Injection?Gilead has signed royalty-free licensing deals with six manufacturers to produce lenacapavir generics in 120 low- and middle-income countries. But critics point out that many middle-income nations, such as some in Latin America, are left out.Meanwhile, in the U.S., states with strong support for PrEP programs have already seen a 38% decline in HIV infections. In contrast, states without similar support saw a 27% increase, according to The Lancet HIV.With Medicaid cuts looming and the Supreme Court considering a case that could overturn the requirement for insurers to cover PrEP without copays, the long-term reach of Yeztugo may be compromised.“We could be standing on the verge of eliminating new HIV infections,” said Carl Schmid of the HIV+Hepatitis Policy Institute. “But without the right policies, this will remain a medical miracle out of reach for too many.”What Comes Next In the HIV Battle?Gilead is already working on a once-a-year formulation of lenacapavir to make prevention even more accessible. The Global Fund aims to reach two million new PrEP users in the next three years, and Yeztugo could be pivotal to that goal.There’s also ongoing research into self-administered versions of the injection, which would help reduce the need for in-clinic visits—especially vital for reaching marginalized populations.The FDA’s approval of Yeztugo is more than a regulatory milestone—it’s a paradigm shift in HIV prevention strategy. Whether this breakthrough can live up to its promise will depend on how quickly and equitably it can be delivered.

fda approves hiv shot that’s 99.9% effective; is this the beginning of the end for the viral epidemic?

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Skin Cancer Diagnoses See A Boost With The Help Of AI

Quick Stories

Do Covid-19 At-Home Tests Detect The New Variants?

Wildfire Smoke Could Fuel Flu And COVID-19 Outbreaks

Can A Single Blood Sample Predict Your Lifespan?

Health Conditions A-Z

Do Covid-19 At-Home Tests Detect The New Variants?

Wildfire Smoke Could Fuel Flu And COVID-19 Outbreaks

Skin Cancer Diagnoses See A Boost With The Help Of AI